In the last six months I've collected reports from 94 families that have tried GcMAF with their children affected by autism, and the results are very encouraging.
(PRWEB UK) 29 June 2012
Dr Nicola Antonucci in Italy recently reported on the treatment of 94 children with autism, 83 reported significant improvements. Dr Bradstreet in the USA also reports a high success rate using GcMAF therapy, with many parental anecdotes available on his website. The clinic in Germany has stated that they believe GcMAF to be the most important discovery in the treatment of autism to date.
Dr Bradstreet tested hundreds of children for nagalase levels and found over 80% had very high levels. High nagalase indicates the presence of viruses and a severely weakened immune system, and 46 research papers by over 100 eminent scientists state GcMAF is indicated in these circumstances.
GcMAF is a key component in the immune system: generally speaking, healthy people have it, people with chronic diseases do not. Immuno Biotech Ltd (gcmaf.eu) extracts, sterilises and purifies GcMAF in their Oxford laboratories, and supplied all the clinics above.
The most commonly reported improvements concern cognitive abilities, attention and focus, learning and understanding, receptiveness and awareness to the environment; language abilities both in speech and understanding; social skills and improvements in behaviour and appropriateness.
As GcMAF is a naturally occurring substance in a healthy immune system, the side effects are minimal. They can include a low grade fever for a few hours as the immune system starts to tackle viruses, and if the dose is too high, an initial aggravation of some of the symptoms, such as anger and aggression which wears off after two to three weeks. Most show no side effects.
Daniel, aged 5, was diagnosed with autism at aged 2 ½ with severe symptoms. Ever since, his family has worked hard to control his diet in order to prevent the painful symptoms that he was experiencing through his digestive problems . His diet is casein free, gluten free and, more recently, ketogenic. All factory food is avoided, as are sugars, wheat, peanuts and yeast.
However, despite many medications, Daniel did not see significant improvement until he was put onto the GcMAF therapy. Almost from the first injection, improvements were seen. A new calm settled over the household.
Within the first 8 weeks, Daniel had seen improvements in composure, language, awareness and relationships: Between the 5th and 6th injections, Daniel became a lot more aware of his surroundings and more spontaneous with his language. By week 7, his parents were reporting that he was the most engaged with life that they had ever seen him. They did not have the regression they experienced with previous treatments.
At about 8 weeks he started to recognise 3D pictures and went from struggling with a six piece jigsaw to completing a 48 piece puzzle overnight. At around this time, his parents introduced him to the ketogenic diet, which they feel has helped enormously with the digestive issues that he suffers with. Part of GcMAF's function is by activating macrophages, and it appears that a good supply of lipids is required, which is provided in a ketogenic diet. By the 16th shot, he was more spontaneous and articulate with his language than ever before, and his clostridia infection had cleared up.
The clostridia had been a major issue with Daniel, as it impacted on his behaviour, causing Tourette type outbursts. These had been very distressing for the whole family, but since the clostridia cleared up, these outbursts have ceased. There has been no recurrence of this infection for the past six months, which the parents had been fighting with antibiotics for 2 ½ years.
There are many signs he is recovering, and the hurdles that were previously impossible to overcome have now been crossed. He is catching up on his learning; his speech and understanding has blossomed, and his parents continue with GcMAF because, although he has improved considerably, he is still a long way behind his peers.
However, as with any medical intervention there are always those that do not respond as expected. Approximately 15% of patients do not show signs of improvements, and occasionally the side effects include increases in the behaviours that GcMAF alleviates in others, which is resolved once the patient stops taking GcMAF. Research is continuing to try to work out the reason why a minority of patients do not benefit, with genetic autism, a type of autism known as fragile X syndrome, viruses concealing themselves with biofilms, and a blocked VDR all being examined.